Vitamin d drug may ease chronic pancreatitis pain
NCT ID NCT05664880
First seen Jun 25, 2026 · Last updated Aug 06, 2026 · Updated 3 times
Summary
This early-phase trial tests whether paricalcitol, a vitamin D analog, can improve quality of life in adults with chronic pancreatitis. Researchers will enroll 24 participants to take either the drug or a placebo for 12 months. The main goal is to see if the study is feasible and acceptable to patients, while also tracking pain and daily function.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Paricalcitol (a vitamin D analog)
- What this could lead to
- If it works, this could point toward a new way to ease pain and improve daily life for people with chronic pancreatitis.
- What could go wrong
- This is a very early, small pilot study with only 24 people. It mainly checks if the idea is feasible, not if it truly works. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jun 2023
- Expected to finish
-
Dec 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Provision of signed and dated informed consent form * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged 18-75 at time of enrollment * Diagnosis of Chronic Pancreatitis episode is not attributable to gallstones (i.e. suspected or definite biliary etiology), medications, trauma or autoimmune pancreatitis. * Ability to take oral medication and be willing to adhere to the dosing regimen * Normal Calcium levels- 8.5 to 10.2 mg/dL * Normal Phosphate levels- 2.8 to 4.5 mg/dL * Normal Parathyroid hormone levels- 10 to 65 pg/mL * For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 1 week after the end of Investigational Product administration * For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner * No prior pancreatic surgery * Pancreatic necrosis, if present, is \<50% (to be verified by radiologist) * No involvement in any interventional trials currently or within 6 months of enrollment Exclusion Criteria: * Pregnancy or lactation * History of autoimmune or traumatic pancreatitis, or sentinel attack of acute necrotizing pancreatitis which results in suspected disconnected duct syndrome * Primary pancreatic tumors - pancreatic ductal adenocarcinoma, suspected cystic neoplasm (\>1 cms in size or main duct involvement), neuroendocrine tumors, and other uncommon tumors. * Pancreatic metastasis from other malignancies * History of solid organ transplant, HIV/AIDS. * Abnormal lab values: calcium, phosphate, or parathyroid hormone * Known isolated pancreatic exocrine insufficiency (e.g. in the absence of any eligible inclusion criteria) * Participants must not have medical or psychiatric illnesses or ongoing substance abuse that in the investigator's opinion would compromise their ability to tolerate study interventions or participate in longitudinal follow up * Patients with known abnormal creatinine (GFR \< 30) or renal failure (applies to patients with chronic upper abdominal pain of suspected pancreatic origin and suspected CP. * Known Pregnancy. All participants of childbearing potential, except if post-menopausal \[i.e. no menses for ≥2 years\] or had a hysterectomy, bilateral tubal ligation/clip (surgical sterilization) or surgical removal of both the ovaries), must have a negative urine or serum B-HCG pregnancy test documented within 2 days prior to any endoscopic or radiologic procedures done for research purposes. Any standard of care tests will follow institutional policies regarding pregnancy test * Currently incarcerated * Inability to tolerate MRI
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic pancreatitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cedars-Sinai Medical Center
Los Angeles, California, 90048, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can clearing a blocked pancreatic duct restore insulin production?
- Can a vast image library unlock better pancreatic diagnoses?
- Can a 1,500-Patient biobank unlock the secrets of chronic pancreatitis?
- Blood and gut clues may flag pancreatic cancer risk early
- Can a lung drug tame the pain of chronic pancreatitis?
- Can a Decades-Old drug reverse pancreatic scarring?